Pramipexole reverses Parkinson's disease-related motivational deficits in rats

Movement Disorders

Volumn 29, Issue 7, 2014, Pages 912-920

  Favier, Mathieu ^a,b   Duran, Theo ^a,b   Carcenac, Carole ^a,b   Drui, Guillaume ^a,b   Savasta, Marc ^a,b,c   Carnicella, Sebastien ^a,b  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Apathy; D2 D3 receptors; Dopamine; Parkinson's disease; Pramipexole

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; OXIDOPAMINE; PRAMIPEXOLE; SUCROSE; BENZOTHIAZOLE DERIVATIVE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEAFFERENTATION; DRUG SELF ADMINISTRATION; INSTRUMENTAL CONDITIONING; LOCOMOTION; MICRODIALYSIS; MOTIVATIONAL DEFICIT; NEUROLOGIC DISEASE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STEREOTAXIC SURGERY; SUGAR INTAKE; VENTRAL TEGMENTUM; ANIMAL; ANIMAL BEHAVIOR; APATHY; BRAIN; DISEASE MODEL; DRUG EFFECTS; METABOLISM;

ANIMALS; APATHY; BEHAVIOR, ANIMAL; BENZOTHIAZOLES; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; PARKINSON DISEASE; RATS; RECEPTORS, DOPAMINE;

EID: 84902267728     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25837     Document Type: Article

References (58)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-1793.
2. Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:928-930.
3. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
4. Isella V, Melzi P, Grimaldi M, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002;17:366-371.
5. Marin R. Differential diagnosis and classification of apathy. Am J Psychiatry 1990;147:22-30.
6. Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008;23:964-969.
7. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006;16:916-928.
8. Starkstein SE, Leentjens AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008;79:1088-1092.
9. Schmidt L, d'Arc BF, Lafargue G, et al. Disconnecting force from money: effects of basal ganglia damage on incentive motivation. Brain 2008;131:1303-1310.
10. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008;15(Suppl 1):14-20.
11. Pedersen KF, Alves G, Bronnick K, Aarsland D, Tysnes OB, Larsen JP. Apathy in drug-naive patients with incident Parkinson's disease: the Norwegian ParkWest study. J Neurol 2009;257:217-223.
12. Drapier D, Drapier S, Sauleau P, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006;253:1083-1091.
13. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111-1127.
14. Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012;135:1463-1477.
15. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002;40:2257-2267.
16. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009;31:89-98.
17. Ishizaki J, Mimura M. Dysthymia and apathy: diagnosis and treatment. Depress Res Treat 2011;2011:893905.
18. Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 2010;6:487-498.
19. Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA. Deep brain stimulation: from neurology to psychiatry? Trends Neurosci 2010;33:474-484.
20. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.
21. Chase TN. Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment. Neurotox Res 2011;19:266-278.
22. Santangelo G, Trojano L, Barone P, Errico D, Grossi D, Vitale C. Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol 2013;27;501-513.
23. Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry 2013 Feb 12. doi: 10.1038/mp.2013.3.
24. Pioli EY, Meissner W, Sohr R, Gross CE, Bezard E, Bioulac BH. Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience 2008;153:1213-1224.
25. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28:1065-1078.
26. Schwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 1996;49:215-266.
27. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Fourth ed. San Diego, CA: Elsevier Academic Press; 1998.
28. Brizard M, Carcenac C, Bemelmans AP, Feuerstein C, Mallet J, Savasta M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol Dis 2006;21:90-101.
29. Chritin M, Feuerstein C, Savasta M. Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat. Brain Res Mol Brain Res 1993;19:318-322.
30. Kirik D, Rosenblad C, Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998;152:259-277.
31. Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D. GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci U S A 2008;105:8114-8119.
32. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996;50:275-331.
33. Maj J, Rogoi Z, Margas W, Kata M, Dziedzicka-Wasylewska M. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Transm 2000;107:1369-1379.
34. Maj J, Rogóz Z, Skuza G, Kołodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 1997;324:31-37.
35. Chang WL, Breier MR, Yang A, Swerdlow NR. Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats. Pharmacol Biochem Behav 2011;99:634-638.
36. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007;191:391-431.
37. Wise R. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 1982;5:39-53.
38. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ. Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behav Brain Res 2009;199:89-102.
39. Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci 2010;11:760-772.
40. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci 2006;7:464-476.
41. Labandeira-Garcia JL, Rozas G, Lopez-Martin E, Liste I, Guerra MJ. Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression. Exp Brain Res 1996;108:69-84.
42. Jeon BS, Jackson-Lewis V, Burke RE. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 1995;4:131-137.
43. Zuch CL, Nordstroem VK, Briedrick LA, Hoernig GR, Granholm AC, Bickford PC. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol 2000;427:440-454.
44. Fornaguera J, Schwarting RK. Early behavioral changes after nigro-striatal system damage can serve as predictors of striatal dopamine depletion. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:1353-1368.
45. Santini E, Valjent E, Fisone G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 2008;275:1392-1399.
46. Delaville C, Chetrit J, Abdallah K, et al. Emerging dysfunctions consequent to combined monoaminergic depletions in parkinsonism. Neurobiol Dis 2012;45:763-773.
47. Agid Y, Ruberg M, Javoy-Agid F, et al. Are dopaminergic neurons selectively vulnerable to Parkinson's disease? Adv Neurol 1993;60:148-164.
48. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14:153-197.
49. Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006;5:25-43.
50. Carnicella S, Drui G, Boulet S, et al. Specific reversal of loss of motivated behaviors by dopamine D3 receptors stimulation: therapeutic implication for Parkinson's disease-related neuropsychiatric symptoms. 11th International Basal Ganglia Society Meeting, March 3-7, 2013, Eilat, Israel.
51. 3 expression in rat striatum. J Pharmacol Sci 2012;120:133-137.
52. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 1997;94:3363-3367.
53. Bézard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.
54. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009;24:1561-1570.
55. Voon V, Potenza MN, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr Opin Neurol 2007;20:484-491.
56. Agid Y, Ruberg M, Dubois B, Javoy-Agid F. Biochemical substrates of mental disturbances in Parkinson's disease. Adv Neurol 1984;40:211-218.
57. Engeln M, Ahmed SH, Vouillac C, Tison F, Bezard E, Fernagut PO. Reinforcing properties of pramipexole in normal and parkinsonian rats. Neurobiol Dis 2012;49:79-86.
58. Riddle JL, Rokosik SL, Napier TC. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls. Behav Brain Res 2012;233:15-23.